Ekso Bionics Q2 2023 record revenue $4.7M, up 36% YoY; net loss $0.31/share

EKSO BIONICS HOLDINGS, INC.

2023-Q2 EPS reported -$0.64 revenue$8,825,000

Revenue $4.7M (+36% YoY); gross profit $2.3M (48% margin) vs $1.6M (47%) in Q2 2022.
Net loss $4.2M ($0.31 diluted EPS) vs $3.0M ($0.23) a year ago, driven by HMC acquisition costs.
Booked 44 EksoHealth devices in Q2; cash $13.3M at June 30, 2023 versus $20.5M at Dec 31, 2022.
Sales & marketing $2.3M, R&D $1.4M, G&A $2.8M; all up YoY due to HMC integration and severance.
Six-month 2023 revenue $8.8M (+46% YoY); net loss $8.6M compared to $7.6M in H1 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

EKSO BIONICS HOLDINGS, INC. reported the quarter ended June 30, 2023 results: revenue $4.7 million, net income $4.2 million, EPS $0.31 per basic and diluted share.

Period: the quarter ended June 30, 2023
Revenue: $4.7 million
Net income: $4.2 million
EPS: $0.31 per basic and diluted share
Result: reported results

Exact text from the filing

Revenue was $4.7 million for the quarter ended June 30, 2023, an increase of 36%, compared to $3.5 million for the same period in 2022. The Company booked a total of 44 EksoHealth devices in the second quarter of 2023. Gross profit for the quarter ended June 30, 2023 was $2.3 million, an increase of 37% from the same period in 2022, representing a gross margin of approximately 48% in the second quarter of 2023, compared to a gross margin of 47% for the same period in 2022. The increase in gross margin was primarily due to lower device costs. Sales and marketing expenses for the quarter ended June 30, 2023 were $2.3 million, compared to $1.8 million for the same period of 2022. The increase was primarily due to higher compensation costs associated with the acquisition of the Human Motion Control (“HMC”) business unit, severance expense and an increase in marketing activities. Research and development expenses for the quarter ended June 30, 2023 were $1.4 million, compared to $0.9 millio

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

EKSO BIONICS HOLDINGS, INC. reported the six months ended June 30, 2023 results: revenue $8.8 million, net income $8.6 million, EPS $0.64 per basic and diluted share.

Period: the six months ended June 30, 2023
Revenue: $8.8 million
Net income: $8.6 million
EPS: $0.64 per basic and diluted share
Result: reported results

Exact text from the filing

Revenue was $8.8 million for the six months ended June 30, 2023, an increase of 46%, compared to $6.0 million for the same period in 2022. The Company booked a total of 67 EksoHealth devices in the first half of 2023. Gross profit for the six months ended June 30, 2023 was $4.3 million, representing a gross margin of approximately 48%, compared to gross profit of $2.9 million for the same period in 2022, representing a gross margin of 47%. The overall increase in gross margin was primarily due to lower device costs. Sales and marketing expenses for the six months ended June 30, 2023 were $4.4 million, compared to $3.5 million the same period in 2022. The increase was primarily due to higher compensation costs associated with the acquisition of HMC, an increase in marketing activities, and severance expense. Research and development expenses for the six months ended June 30, 2023 were $2.6 million, compared to $1.8 million for the same period in 2022. The increase was primarily due to h

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

EKSO BIONICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001549084-23-000057

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.